• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » PreHevbrio [Hepatitis B Vaccine (Recombinant)]

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

PreHevbrio [Hepatitis B Vaccine (Recombinant)]

  • Profile

Profile

Contact Information

Contact: VBI Vaccines
Website: https://www.prehevbrio.com/

Currently Enrolling Trials

    Show More

    General Information

    PreHevbrio [Hepatitis B Vaccine (Recombinant)] induces antibodies to 3 HBV surface antigens. 

    PreHevbrio is specifically indicated for use in adults for the prevention of infection caused by all known subtypes of hepatitis B virus.

    PreHevbrio is supplied as a suspension for intramuscular injection. Administer a series of three doses (1.0 mL each) on a 0-, 1- and 6-month schedule

    Mechanism of Action

    PreHevbrio [Hepatitis B Vaccine (Recombinant)] induces antibodies to 3 HBV surface antigens: the small (S), middle (pre-S2) and large (pre-S1) hepatitis B surface antigens. 

    Side Effects

    Adverse effects associated with the use of PreHevbrio may include, but are not limited to, the following:

    • injection site pain and tenderness
    • headache
    • fatigue
    • myalgia

    Clinical Trial Results

    FDA Approval was based on the results from two Phase 3 clinical studies, PROTECT and CONSTANT, which compared PreHevbrio to Engerix-B, a single-antigen HBV vaccine. Data from the PROTECT study showed that PreHevbrio elicited higher rates of seroprotection in all subjects age 18+ (91.4% vs. 76.5%), including in adults age 45+ (89.4% vs. 73.1%).  In the CONSTANT study seroprotection after two doses, at Day 168, was 90.4% for VBI’s 3-antigen vaccine candidate compared to 51.6% for Engerix-B, increasing to 99.3% and 94.8%, respectively, after the third dose. 

    Approval Date: 2021-12-01
    Company Name: VBI Vaccines
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing